Illumina, and Ovation.io, a leader in creating advanced multiomic datasets, announced the launch of the largest commercially available clinical multiomic dataset focused on patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. This landmark dataset includes detailed insights from 25,000 patients and will be made available to the pharmaceutical industry to support next-generation drug discovery and development.
This collaboration represents a significant step forward in leveraging multimodal data to deepen biological understanding and fuel innovation across the healthcare ecosystem.
According to a 2024 health tracking poll by the Kaiser Family Foundation, one in eight adults in the United States has used GLP-1 receptor agonists. Despite the growing adoption, research published in Diabetes & Metabolic Syndrome (2024) indicates that approximately 40% of patients with Type 2 diabetes do not experience an adequate therapeutic response to GLP-1 treatments. The new dataset aims to close this gap by enabling targeted research into drug response variability, expanding indications, and uncovering novel biomarkers for nonresponsive patient groups.
Also Read: Twist Bioscience Expands Its Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System
“The power of whole-genome and multiomic insights to impact all diseases is coming into focus, and metabolic disease is a prime example,” said Todd Christian, senior vice president of Services, Arrays, and Genomic Access at Illumina. “This collaboration and its novel clinical dataset will be crucial to advancing the next wave of these potential life-changing therapies, and ensuring more patients can benefit from them.”
Under a multiyear agreement, Illumina and Ovation are delivering an integrated dataset comprising genomic, proteomic, and phenotypic data. The comprehensive resource includes both responsive and nonresponsive patient profiles, providing a unique opportunity to better understand the molecular mechanisms influencing GLP-1 treatment outcomes.
This initiative is designed to unlock new therapeutic pathways, support indication expansion, and identify precision biomarkers and drug targets that address unmet needs among patients with diabetes, obesity, and related metabolic conditions.
“We’re proud to collaborate with Illumina to develop one of the world’s largest WGS omics datasets, supporting the millions of patients with diabetes and obesity,” said Marty Miller, chief revenue officer of Ovation. “Through this effort—and for the first time at scale with the inclusion of proteomics-we aim to equip the pharmaceutical industry with the insights needed to better understand the varying effectiveness and side effects of GLP-1 receptor agonists across individual patients.”